Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRQ-01 (oral transmucosal fentanyl patch) for cancer breakthrough pain
jRCT2080222864Phase 3
- Sponsor
- Maruishi Pharmaceutical Co., Ltd.
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fentanyl in breakthrough cancer pain (BTcP) (2 arms), sponsored by Maruishi Pharmaceutical Co., Ltd.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on jRCT2080222864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222864.